ALK and non-small cell lung carcinoma: Examples include osimertinib, which targets the p.T790M mutation in EGFR emerging in NSCLC patients treated with EGFR tyrosine kinase inhibitors (TKIs); or second‐ and third‐generation ALK TKIs, such as brigatinib or lorlatinib, that show efficacy in patients harboring resistance mutations in ALK (Zhang et al., 2016).